![](https://www.udayavani.com/wp-content/uploads/2025/02/net-India-pti-fiel-415x233.png)
![](https://www.udayavani.com/wp-content/uploads/2025/02/net-India-pti-fiel-415x233.png)
Team Udayavani, Sep 5, 2020, 4:03 PM IST
Russia’s new Covid-19 vaccine has passed early trial test and the patients involved in early tests developed antibodies with no serious adverse effects
A research article published in The Lancet reported that two small trials, each involving 38 healthy adults aged between 18 and 60, were given a two-part immunisation.
As per the report, the participants were monitored over 42 days and all developed antibodies within the first three weeks.
Also, over 76 participants of these trials would be monitored up to 180 days and more rigorous phase 3 clinical trial was planned with the involvement of 40,000 volunteers from different age and risk groups.
The data showed that the vaccine was “safe, well tolerated, and does not cause serious adverse events in healthy adult volunteers”.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
To ban or not to ban? Countries debate regulations on smartphone usage in schools
Air pollution, extreme weather could increase risk of prolonged pregnancy: Study
Carbohydrate cravings may be related to overall severity of depression: Study
SAHAYOGA: Comprehensive care for children with Type 1 Diabetes launched at MAHE Manipal
Newer Advances in Blood Cancer Treatment
India Nets: Shami works on lengths with Morkel, Pant recovers after freak hit by Hardik shot
To ban or not to ban? Countries debate regulations on smartphone usage in schools
PM didn’t tell his good friend about country’s outrage over handcuffing Indian deportees: Congress
Maha Kumbh: Akhilesh seeks compensation to kin of devotees killed in accidents
“Namma Sante” buzz: From coconut shell art to pure honey delights!
You seem to have an Ad Blocker on.
To continue reading, please turn it off or whitelist Udayavani.